Analyst consensus rating
Novo Nordisk Analyst Rating: Hold
Direct answer
Novo Nordisk's consensus rating is Hold.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $44.82.
Forecast evidence checked October 27, 2026.
Get free Novo Nordisk email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $38.67
- Average price target
- $44.82
- High price target
- $61.41
- Low price target
- $39.50
- Low target gap
- +2.2%
- Target upside
- +15.9%
- High target gap
- +58.8%
- Target range width
- 56.7%
- Consensus rating
- Hold
- Analysts
- 12
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Novo Nordisk?
Novo Nordisk has a verified Hold consensus. The same dataset has an average price target of $44.82.
How far are Novo Nordisk's low and high targets from the recorded price?
The low target implies +2.2%, while the high target implies +58.8%.
How many analysts are included in Novo Nordisk's consensus?
The verified consensus includes 12 analysts.
How is Novo Nordisk's target upside or downside calculated?
The average target of $44.82 is divided by the recorded price of $38.67, then one is subtracted to produce +15.9%. This does not guarantee a future return.
When was Novo Nordisk's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.